129 related articles for article (PubMed ID: 18079740)
1. JAK2 Mutations are present in all cases of polycythemia vera.
Wang YL; Vandris K; Jones A; Cross NC; Christos P; Adriano F; Silver RT
Leukemia; 2008 Jun; 22(6):1289. PubMed ID: 18079740
[No Abstract] [Full Text] [Related]
2. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
Yoo JH; Park TS; Maeng HY; Sun YK; Kim YA; Kie JH; Cho EH; Song J; Lee KA; Suh B; Choi JR
Cancer Genet Cytogenet; 2009 Feb; 189(1):43-7. PubMed ID: 19167611
[TBL] [Abstract][Full Text] [Related]
3. Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera.
Grünebach F; Bross-Bach U; Kanz L; Brossart P
Leukemia; 2006 Dec; 20(12):2210-1. PubMed ID: 17008888
[No Abstract] [Full Text] [Related]
4. JAK2 mutations other than V617F: a novel mutation and mini review.
Karow A; Waller C; Reimann C; Niemeyer CM; Kratz CP
Leuk Res; 2008 Feb; 32(2):365-6. PubMed ID: 17466371
[No Abstract] [Full Text] [Related]
5. Frequency of Janus associated kinase 2 (V617F) mutation in patients of polycythemia vera.
Khattak SA; Ahmed S; Anwar J; Bozdar M
J Coll Physicians Surg Pak; 2012 Feb; 22(2):80-3. PubMed ID: 22313642
[TBL] [Abstract][Full Text] [Related]
6. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
7. Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients.
Kouroupi E; Zoi K; Parquet N; Zoi C; Kiladjian JJ; Grigoraki V; Vainchenker W; Lellouche F; Marzac C; Schlageter MH; Dosquet C; Scott LM; Fenaux P; Loukopoulos D; Chomienne C; Cassinat B
Br J Haematol; 2008 Aug; 142(4):676-9. PubMed ID: 18503583
[No Abstract] [Full Text] [Related]
8. JAK2 V617F positive polycythemia Vera in a child with neurofibromatosis type I.
Berman JN; Greer WL; Archambeault S; Loh ML; Riddell C; Morash B; Dumas N; Fernandez CV; Ludman MD
Pediatr Blood Cancer; 2008 Nov; 51(5):689-91. PubMed ID: 18623221
[TBL] [Abstract][Full Text] [Related]
9. JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications.
Tefferi A
N Engl J Med; 2007 Feb; 356(5):444-5. PubMed ID: 17267904
[No Abstract] [Full Text] [Related]
10. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
Martínez-Avilés L; Besses C; Alvarez-Larrán A; Cervantes F; Hernández-Boluda JC; Bellosillo B
Haematologica; 2007 Dec; 92(12):1717-8. PubMed ID: 18056003
[TBL] [Abstract][Full Text] [Related]
11. Concurrent JAK2(V617F) mutation and MTHFR(C677T) homozygosity in an adolescent with polycythemia vera: case report and discussion.
Ehmann MR; Goodenough CJ; Lotterman CD; Warrier RP
Clin Pediatr (Phila); 2013 Jul; 52(7):671-4. PubMed ID: 22626845
[No Abstract] [Full Text] [Related]
12. Development of a quantitative real-time polymerase chain reaction assay for the detection of the JAK2 V617F mutation.
Wolstencroft EC; Hanlon K; Harries LW; Standen GR; Sternberg A; Ellard S
J Mol Diagn; 2007 Feb; 9(1):42-6. PubMed ID: 17251334
[TBL] [Abstract][Full Text] [Related]
13. Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera.
Scott LM; Beer PA; Bench AJ; Erber WN; Green AR
Br J Haematol; 2007 Nov; 139(3):511-2. PubMed ID: 17910642
[No Abstract] [Full Text] [Related]
14. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?
Verstovsek S; Silver RT; Cross NC; Tefferi A
Leukemia; 2006 Nov; 20(11):2067. PubMed ID: 16990780
[No Abstract] [Full Text] [Related]
15. The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera.
Olcaydu D; Skoda RC; Looser R; Li S; Cazzola M; Pietra D; Passamonti F; Lippert E; Carillo S; Girodon F; Vannucchi A; Reading NS; Prchal JT; Ay C; Pabinger I; Gisslinger H; Kralovics R
Leukemia; 2009 Oct; 23(10):1924-6. PubMed ID: 19440215
[No Abstract] [Full Text] [Related]
16. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
17. A multiplexed fragment analysis-based assay for detection of JAK2 exon 12 mutations.
Furtado LV; Weigelin HC; Elenitoba-Johnson KS; Betz BL
J Mol Diagn; 2013 Sep; 15(5):592-9. PubMed ID: 23810504
[TBL] [Abstract][Full Text] [Related]
18. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients.
Butcher CM; Hahn U; To LB; Gecz J; Wilkins EJ; Scott HS; Bardy PG; D'Andrea RJ
Leukemia; 2008 Apr; 22(4):870-3. PubMed ID: 17914411
[No Abstract] [Full Text] [Related]
19. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera.
Tefferi A; Strand JJ; Lasho TL; Knudson RA; Finke CM; Gangat N; Pardanani A; Hanson CA; Ketterling RP
Leukemia; 2007 Sep; 21(9):2074-5. PubMed ID: 17476276
[No Abstract] [Full Text] [Related]
20. Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient.
Rao N; Butcher CM; Lewis ID; Ross DM; Melo JV; Scott HS; Bardy PG; D'Andrea RJ
Br J Haematol; 2012 Jan; 156(2):268-70. PubMed ID: 21859430
[No Abstract] [Full Text] [Related]
[Next] [New Search]
